CL2021003032A1 - Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton - Google Patents

Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton

Info

Publication number
CL2021003032A1
CL2021003032A1 CL2021003032A CL2021003032A CL2021003032A1 CL 2021003032 A1 CL2021003032 A1 CL 2021003032A1 CL 2021003032 A CL2021003032 A CL 2021003032A CL 2021003032 A CL2021003032 A CL 2021003032A CL 2021003032 A1 CL2021003032 A1 CL 2021003032A1
Authority
CL
Chile
Prior art keywords
methods
bruton
chronic spontaneous
tyrosine kinase
kinase inhibitor
Prior art date
Application number
CL2021003032A
Other languages
English (en)
Spanish (es)
Inventor
Souvik Bhattacharya
Bruno Bieth
Maciej Cabanski
Bruno Cenni
Buck Stefan De
Martin Kaul
Arvind Kinhikar
Andrijana Radivojevic
Thomas Severin
Julian Storim
Garami Alessandra Vitaliti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2021003032A1 publication Critical patent/CL2021003032A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2021003032A 2019-05-23 2021-11-17 Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton CL2021003032A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962851996P 2019-05-23 2019-05-23

Publications (1)

Publication Number Publication Date
CL2021003032A1 true CL2021003032A1 (es) 2022-09-09

Family

ID=70918751

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003032A CL2021003032A1 (es) 2019-05-23 2021-11-17 Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton

Country Status (22)

Country Link
US (2) US12419889B2 (cg-RX-API-DMAC7.html)
EP (2) EP4599894A3 (cg-RX-API-DMAC7.html)
JP (2) JP7568651B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220012281A (cg-RX-API-DMAC7.html)
CN (1) CN113795255A (cg-RX-API-DMAC7.html)
AU (2) AU2020280272B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021022602A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138081A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003032A1 (cg-RX-API-DMAC7.html)
DK (1) DK3972604T3 (cg-RX-API-DMAC7.html)
ES (1) ES3039974T3 (cg-RX-API-DMAC7.html)
FI (1) FI3972604T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251001T1 (cg-RX-API-DMAC7.html)
IL (1) IL286983B2 (cg-RX-API-DMAC7.html)
LT (1) LT3972604T (cg-RX-API-DMAC7.html)
MX (2) MX2021013942A (cg-RX-API-DMAC7.html)
PL (1) PL3972604T3 (cg-RX-API-DMAC7.html)
PT (1) PT3972604T (cg-RX-API-DMAC7.html)
RS (1) RS67141B1 (cg-RX-API-DMAC7.html)
SI (1) SI3972604T1 (cg-RX-API-DMAC7.html)
TW (1) TWI868139B (cg-RX-API-DMAC7.html)
WO (1) WO2020234782A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3972604T3 (fi) * 2019-05-23 2025-09-01 Novartis Ag Brutonin tyrosiinikinaasin estäjä käytettäväksi kroonisen spontaanin urtikarian hoidossa
IL310975A (en) 2021-09-03 2024-04-01 Novartis Ag LOU064 for the treatment of multiple sclerosis
CA3239276A1 (en) 2021-12-14 2023-06-22 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用lou064治療化膿性汗腺炎之方法
KR102834740B1 (ko) * 2023-04-10 2025-07-17 아주대학교산학협력단 Hsp10 또는 이의 항체를 유효성분으로 포함하는 만성 자발적 두드러기의 진단을 위한 바이오마커 조성물
WO2024235163A1 (zh) * 2023-05-12 2024-11-21 武汉人福创新药物研发中心有限公司 Btk抑制剂的用途和单剂量药物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200924781A (en) 2007-09-14 2009-06-16 Janssen Pharmaceutica Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EP3092250A4 (en) 2014-01-08 2017-05-24 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
WO2016079669A1 (en) 2014-11-19 2016-05-26 Novartis Ag Labeled amino pyrimidine derivatives
FI3972604T3 (fi) 2019-05-23 2025-09-01 Novartis Ag Brutonin tyrosiinikinaasin estäjä käytettäväksi kroonisen spontaanin urtikarian hoidossa

Also Published As

Publication number Publication date
AU2025252618A1 (en) 2025-11-06
TW202537625A (zh) 2025-10-01
IL286983B1 (en) 2025-09-01
HRP20251001T1 (hr) 2025-10-24
LT3972604T (lt) 2025-09-10
TWI868139B (zh) 2025-01-01
CN113795255A (zh) 2021-12-14
BR112021022602A2 (pt) 2022-01-04
DK3972604T3 (da) 2025-09-15
PL3972604T3 (pl) 2025-09-22
IL286983B2 (en) 2026-01-01
JP2022533981A (ja) 2022-07-27
IL286983A (en) 2021-12-01
TW202110450A (zh) 2021-03-16
AU2020280272A1 (en) 2021-11-18
ES3039974T3 (en) 2025-10-28
SI3972604T1 (sl) 2025-09-30
JP7568651B2 (ja) 2024-10-16
EP3972604A1 (en) 2022-03-30
RS67141B1 (sr) 2025-09-30
US20220184074A1 (en) 2022-06-16
AU2020280272B2 (en) 2025-07-24
FI3972604T3 (fi) 2025-09-01
EP4599894A2 (en) 2025-08-13
KR20220012281A (ko) 2022-02-03
CA3138081A1 (en) 2020-11-26
EP4599894A3 (en) 2025-11-12
JP2024178168A (ja) 2024-12-24
US12419889B2 (en) 2025-09-23
WO2020234782A1 (en) 2020-11-26
EP3972604B1 (en) 2025-06-04
PT3972604T (pt) 2025-08-26
MX2021013942A (es) 2022-01-04
MX2024014626A (es) 2025-01-09
US20250375446A1 (en) 2025-12-11

Similar Documents

Publication Publication Date Title
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
DOP2020000241A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
MX2019012884A (es) Terapia de combinacion.
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
MX2018016330A (es) Combinaciones para tratamiento del cáncer.
AR111233A1 (es) Inhibidores de tyk2, usos y métodos para la producción de los mismos
MX2024014626A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton
MX2023000812A (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
MX2023002325A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
CO2022008001A2 (es) Métodos para el tratamiento de trastornos depresivos
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
CO2022015891A2 (es) Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres
MX2022003845A (es) Tratamientos cognitivos medicinales.
CL2021001830A1 (es) Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa
CR20210661A (es) Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos
EA202190360A1 (ru) Комбинированная терапия
MX2022001227A (es) Metodos de tratamiento del cancer multifocal.
CL2025000332A1 (es) Tratamiento de la urticaria con inhibidores de jak.
AR121415A1 (es) INHIBIDORES DE LA QUINASA p38 QUE REDUCEN LA EXPRESIÓN DE DUX4 Y DE LOS GENES CORRIENTE ABAJO PARA USO EN EL TRATAMIENTO DE FSHD
AR114854A1 (es) Métodos para el tratamiento del cáncer
AR108792A1 (es) Composiciones que comprenden timolol